67 reports of this reaction
1.3% of all ETOMIDATE reports
#20 most reported adverse reaction
ANAPHYLACTIC SHOCK is the #20 most commonly reported adverse reaction for ETOMIDATE, manufactured by Hospira, Inc.. There are 67 FDA adverse event reports linking ETOMIDATE to ANAPHYLACTIC SHOCK. This represents approximately 1.3% of all 5,192 adverse event reports for this drug.
Patients taking ETOMIDATE who experience anaphylactic shock should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ANAPHYLACTIC SHOCK is a less commonly reported adverse event for ETOMIDATE, but still significant enough to appear in the safety profile.
In addition to anaphylactic shock, the following adverse reactions have been reported for ETOMIDATE:
The following drugs have also been linked to anaphylactic shock in FDA adverse event reports:
ANAPHYLACTIC SHOCK has been reported as an adverse event in 67 FDA reports for ETOMIDATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
ANAPHYLACTIC SHOCK accounts for approximately 1.3% of all adverse event reports for ETOMIDATE, making it a notable side effect.
If you experience anaphylactic shock while taking ETOMIDATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.